Vafidemstat: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Vafidemstat | {{Short description|An overview of the drug Vafidemstat}} | ||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 123456789 | |||
| image = Vafidemstat.svg | |||
| image_size = 250px | |||
| image_alt = Chemical structure of Vafidemstat | |||
}} | |||
Vafidemstat is a novel | '''Vafidemstat''' is a novel [[pharmaceutical drug]] under investigation for its potential therapeutic effects in various [[neuropsychiatric disorders]]. It is classified as a [[histone deacetylase inhibitor]] (HDAC inhibitor), which modulates the expression of genes by altering the acetylation status of histones. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Vafidemstat functions as an inhibitor | Vafidemstat functions primarily as an HDAC inhibitor. By inhibiting histone deacetylases, it increases the acetylation of histone proteins, leading to a more relaxed chromatin structure and increased [[gene expression]]. This mechanism is thought to underlie its potential therapeutic effects in [[neuropsychiatric disorders]] by modulating the expression of genes involved in [[neurotransmission]], [[neuroplasticity]], and [[inflammation]]. | ||
==Therapeutic Applications== | ==Therapeutic Applications== | ||
Vafidemstat is being | Vafidemstat is being investigated for its use in treating a variety of neuropsychiatric conditions, including: | ||
* | * [[Schizophrenia]] | ||
* | * [[Bipolar disorder]] | ||
* [[Major depressive disorder]] | |||
* [[Autism spectrum disorder]] | |||
The drug's ability to modulate gene expression may help alleviate symptoms associated with these disorders by restoring normal patterns of neuronal activity and connectivity. | |||
==Clinical Trials== | ==Clinical Trials== | ||
Vafidemstat is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are designed to assess its impact on symptom severity, cognitive function, and overall quality of life in patients with neuropsychiatric disorders. | |||
==Side Effects== | |||
As with many HDAC inhibitors, potential side effects of Vafidemstat may include: | |||
* [[Gastrointestinal disturbances]] | |||
* [[Fatigue]] | |||
* [[Headache]] | |||
* [[Dizziness]] | |||
Ongoing clinical trials aim to further elucidate the safety profile of Vafidemstat. | |||
==Research and Development== | ==Research and Development== | ||
Vafidemstat | The development of Vafidemstat is part of a broader effort to create targeted therapies for complex neuropsychiatric conditions. By focusing on epigenetic modulation, researchers hope to provide more effective treatments with fewer side effects compared to traditional [[psychotropic medications]]. | ||
==Related Pages== | |||
* [[Histone deacetylase inhibitor]] | |||
* [[Neuropsychiatric disorder]] | |||
* [[Epigenetics]] | |||
[[Category: | [[Category:Pharmaceutical drugs]] | ||
[[Category: | [[Category:Histone deacetylase inhibitors]] | ||
[[Category: | [[Category:Experimental drugs]] | ||
<gallery> | |||
File:Vafidemstat.svg|Vafidemstat | |||
</gallery> | |||
Latest revision as of 01:28, 20 February 2025
An overview of the drug Vafidemstat
| Vafidemstat | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Vafidemstat is a novel pharmaceutical drug under investigation for its potential therapeutic effects in various neuropsychiatric disorders. It is classified as a histone deacetylase inhibitor (HDAC inhibitor), which modulates the expression of genes by altering the acetylation status of histones.
Mechanism of Action[edit]
Vafidemstat functions primarily as an HDAC inhibitor. By inhibiting histone deacetylases, it increases the acetylation of histone proteins, leading to a more relaxed chromatin structure and increased gene expression. This mechanism is thought to underlie its potential therapeutic effects in neuropsychiatric disorders by modulating the expression of genes involved in neurotransmission, neuroplasticity, and inflammation.
Therapeutic Applications[edit]
Vafidemstat is being investigated for its use in treating a variety of neuropsychiatric conditions, including:
The drug's ability to modulate gene expression may help alleviate symptoms associated with these disorders by restoring normal patterns of neuronal activity and connectivity.
Clinical Trials[edit]
Vafidemstat is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are designed to assess its impact on symptom severity, cognitive function, and overall quality of life in patients with neuropsychiatric disorders.
Side Effects[edit]
As with many HDAC inhibitors, potential side effects of Vafidemstat may include:
Ongoing clinical trials aim to further elucidate the safety profile of Vafidemstat.
Research and Development[edit]
The development of Vafidemstat is part of a broader effort to create targeted therapies for complex neuropsychiatric conditions. By focusing on epigenetic modulation, researchers hope to provide more effective treatments with fewer side effects compared to traditional psychotropic medications.
Related Pages[edit]
-
Vafidemstat
